The Effect of Tobacco Products on Wound Healing

NCT ID: NCT04870970

Last Updated: 2025-01-24

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Total Enrollment: 60 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-05-18
• Study Completion Date: 2027-02-28

Brief Summary

The purpose of this study is to evaluate the effect of various tobacco products (including but not limited to combustible cigarettes, medicinal nicotine, electronic cigarettes, and smokeless tobacco) on cutaneous wound healing. There will also be a non- smoking control group. This study will be designed as a pilot study. The majority of individuals will be recruited from ongoing studies at the University of Minnesota - Tobacco Research Programs.

Detailed Description

Participants will be recruited from ongoing studies will some recruitment of tobacco users and non-smoking controls outside of ongoing studies. In this prospective, cohort study of various tobacco users and non-smokers, a punch biopsy model of wound healing will be used to determine the effects of various tobacco products on inflammatory response and oxidative stress response to wounding:

1. Clinical wound inflammation as assessed by:

1. Thermography,

2. Clinical assessment,

3. Laser Doppler Technologies,

4. Transcutaneous oxygen assessment

2. Biological wound inflammation as assessed by:

1. Cytokine profiles,

2. Histology,

3. Genetic assessment,

4. Epigenetic evaluation

3. Systemic inflammation as assessed by:

1. Biomarkers,

2. Cell counts

Conditions

Smoking; Tobacco Use; Tobacco Smoking

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Tobacco Users

Participants in this group use some form of tobacco.

No interventions assigned to this group

Non-Tobacco Users

Participants in this group do not use tobacco products.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• In good physical health with no unstable or serious medical conditions as determined by the licensed medical professional;
• In stable and good mental health (i.e. not currently, within the past 6 months, experiencing unstable or untreated psychiatric diagnosis, including substance abuse) as determined by the licensed medical professional;

A) Non Smokers

• Has consumed less than 100 cigarettes in his or her lifetime.
• Combustible Tobacco Users
• History of at least 5 years smoking
• Smokers will have exclusively smoked at least 5 cigarettes per day for a minimum of 4 days per week for the past year

B) E-Cigarette Users

• Have not smoked cigarettes in the last month
• Has exclusively used e-cigarettes for at least 3 months
• Has at least 5 instances of using an e cigarettes per day for a minimum of 4 days per week

C) Medicinal Nicotine Users

• Have not smoked cigarettes in the last month
• Has at least 5 instances of using medicinal nicotine per day for a minimum of 4 days per week

D) Smokeless Tobacco Users

• Have not smoked cigarettes in the last month

• Has at least 5 instances of using smokeless tobacco per day for a minimum of 4 days per week

E) Combustible Tobacco and E-Cigarette Dual Users

• Has used a combination of combustible tobacco products and e-cigarettes for the past month.
• Has at least 5 instances of using a combination of combustible tobacco and e-cigarettes per day for a minimum of 4 days per week

F) Combustible Tobacco and Medicinal Nicotine Dual Users

• Has used a combinations of combustible tobacco products and e-cigarettes for the past month.
• Has at least 5 instances of using a combination of combustible tobacco and medicinal nicotine per day for a minimum of 4 days per week

• Current smoker of ≥ 8 cigarettes per day for at least the last 6 months by self-report

Adequate blood counts, and adequate liver and kidney function defined as follows:

<!-- -->

1. Hemoglobin ≥ 9 g/dL for women, ≥ 10 g/dL for men

2. Platelet count ≥ 100 x 109/L

3. Total bilirubin ≤ Institutional upper limit of normal (≤ 1.3 mg/dL for UMMC)

4. ALT ≤ 1.5 times institutional upper limit of normal

5. Creatinine ≤ 1.4 g/dL and estimated GFR ≥ 80 mL/min/1.7m2

Exclusion Criteria

• Any tattoos on the medial upper arm (note that one medial upper arm can have a tattoo, but at least one side does not have a tattoo).
• History of delayed wound healing.
• Intention to quit normal tobacco product use in the next three months.
• Excessive drinking (more than 21 alcoholic drinks per week)
• Taking exclusionary medications (including anti-inflammatory agents) unstable dosing of medications, or unstable control of symptoms for ongoing medical conditions (medications or conditions that would impact biomarkers or patient safety to be determined by the licensed medical professional at each site).
• Active infection (e.g., influenza, cold, respiratory infection, sinus infection), admission to study will be delayed pending improved health;
• Individuals with extremely sensitive skin that may feel the 45 degrees Celsius is too warm
• Pregnant or breastfeeding or plans to become pregnant

2. For participants enrolled in an active Tobacco Research Programs study:

• Pregnant or breastfeeding or plans to become pregnant
• Regular use of other tobacco or smoked products (e.g., cigars, pipes, smokeless tobacco, marijuana) in past 6 months;
• Active infection (e.g., influenza, cold, respiratory infection, sinus infection), admission to study will be delayed pending improved health;
• Unstable medical or psychiatric condition

SMOKERS

Inclusion:

• Currently smoking at least 10 cigarettes per day;

• History of at least 5 years smoking;

• Stable smoking pattern for the past 1 year (<50% change in brand or number of cigarettes smoked).

FORMER SMOKERS

Inclusion:

• History of smoking at least 10 cigarettes per day;
• Quitting over 1 year ago

NEVER SMOKERS

Exclusion:

• Smoking more than 100 cigarettes in their lifetime

NICOTINE REPLACEMENT USERS

• Inclusion/Exclusion dependent on intended sample use

E-CIGARETTE USERS (Addendum study) - Inclusion/Exclusion dependent on intended sample use

SMOKELESS TOBACCO USERS (Addendum study)

• Inclusion/Exclusion dependent on intended sample use

• Daily proton pump inhibitor, H2-blocker (i.e., ranitidine, famotidine), and/or calcium carbonate use

• History of gastric bypass surgery, gastric banding, bowel resection, malabsorption syndromes such as celiac sprue or pancreatic insufficiency, or other conditions that may affect gastric or intestinal absorption of nutrients

• Use of tobacco products other than cigarettes (i.e. snuff, snuz, smokeless tobacco, cigars, pipes), within 7 days of study registration
• Major or chronic medical disease, including heart disease, poorly controlled diabetes, etc., to be adjudicated by the principal investigator
• Known active malignancy
• History of aerodigestive malignancies
• Pregnancy, intension to become pregnant within 3 months of study registration, or lactation. Participants of childbearing potential must have a negative urine pregnancy test within 14 days of starting the assigned intervention
• Antibiotic use within 2 months of study registration by self-report
• History of respiratory tract cancer
• Known allergy to I3C, Sil, or its components
• Psychiatric and/or social situations that would potentially limit compliance with study requirements

• Any tattoos on the medial upper arm (note that one medial upper arm can have a tattoo, but at least one side does not have a tattoo).

• History of delayed wound healing.
• Individuals with extremely sensitive skin that may feel the 45 degrees Celsius is too warm

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Minnesota

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dorothy Hatsukami, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Minnesota

Locations

University of Minnesota

Minneapolis, Minnesota, United States

Countries

United States

Other Identifiers

STUDY00006048

Identifier Type: -

Identifier Source: org_study_id